WO2000033818A1 - Sustained release tablet containing hydrocolloid and cellulose ether - Google Patents
Sustained release tablet containing hydrocolloid and cellulose ether Download PDFInfo
- Publication number
- WO2000033818A1 WO2000033818A1 PCT/US1999/029372 US9929372W WO0033818A1 WO 2000033818 A1 WO2000033818 A1 WO 2000033818A1 US 9929372 W US9929372 W US 9929372W WO 0033818 A1 WO0033818 A1 WO 0033818A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- present
- weight
- hydrocouoid
- cellulose ether
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99968872A EP1137403B1 (en) | 1998-12-11 | 1999-12-10 | Sustained release tablet containing hydrocolloid and cellulose ether |
NZ512288A NZ512288A (en) | 1998-12-11 | 1999-12-10 | Sustained release tablet containing hydrocolloid and cellulose ether |
DE69940557T DE69940557D1 (en) | 1998-12-11 | 1999-12-10 | A HYDROCOLLOID AND A DELIVERY-RELATED TABLET CONTAINING CELLULOSE ETHER |
AU27079/00A AU772891B2 (en) | 1998-12-11 | 1999-12-10 | Sustained release tablet containing hydrocolloid and cellulose ether |
JP2000586311A JP2002531491A (en) | 1998-12-11 | 1999-12-10 | Sustained-release tablet containing hydrocolloid and cellulose ether |
CA002354057A CA2354057C (en) | 1998-12-11 | 1999-12-10 | Sustained release tablet containing hydrocolloid and cellulose ether |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11196498P | 1998-12-11 | 1998-12-11 | |
US60/111,964 | 1998-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000033818A1 true WO2000033818A1 (en) | 2000-06-15 |
WO2000033818A9 WO2000033818A9 (en) | 2001-02-01 |
Family
ID=22341399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/029372 WO2000033818A1 (en) | 1998-12-11 | 1999-12-10 | Sustained release tablet containing hydrocolloid and cellulose ether |
Country Status (9)
Country | Link |
---|---|
US (1) | US6416786B1 (en) |
EP (1) | EP1137403B1 (en) |
JP (1) | JP2002531491A (en) |
AT (1) | ATE424810T1 (en) |
AU (1) | AU772891B2 (en) |
CA (1) | CA2354057C (en) |
DE (1) | DE69940557D1 (en) |
NZ (1) | NZ512288A (en) |
WO (1) | WO2000033818A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003088952A1 (en) | 2002-04-15 | 2003-10-30 | Adams Laboratories, Inc. | Sustained release of guaifenesin combination drugs |
EP1385486A1 (en) * | 2001-04-18 | 2004-02-04 | Nostrum Pharmaceuticals, Inc. | A novel coating for a sustained release pharmaceutical composition |
EP1646367A2 (en) * | 2003-07-21 | 2006-04-19 | Bio-Dar Ltd. | Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
WO2007120385A2 (en) * | 2006-02-17 | 2007-10-25 | Kos Life Sciences, Inc. | Low flush niacin formulation |
US7491383B2 (en) | 2001-05-03 | 2009-02-17 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
US7838032B2 (en) | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
US7985421B2 (en) | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US7985420B2 (en) | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US8012504B2 (en) | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19933289A1 (en) * | 1999-07-15 | 2001-01-18 | Basf Ag | Process for the production of granules from a melt |
KR100548925B1 (en) * | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | Sustained release composition for oral administration of a drug |
ATE364840T1 (en) * | 2002-11-04 | 2007-07-15 | Transform Pharmaceuticals Inc | ANALYSIS OF PHARMACEUTICAL SOLUBILITY AND STABILITY |
AU2004222339A1 (en) * | 2003-03-14 | 2004-09-30 | Nirmal Mulye | A process for preparing sustained release tablets |
US7163101B2 (en) * | 2003-10-30 | 2007-01-16 | William Anthony Harper | Flexible liquid packet with rigid insert |
FR2861990B1 (en) | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | LOW DOSAGE TABLETS WITH POLYMER NETWORK |
US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
KR101366764B1 (en) * | 2005-05-31 | 2014-02-25 | 주식회사 씨티씨바이오 | Manufacturing method of controlled-release tablet containing doxazocin mesylate |
US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
US20080064694A1 (en) * | 2006-09-11 | 2008-03-13 | Auriga Laboratories, Inc. | Multi-Phase Release Methscopolamine Compositions |
US20080069874A1 (en) * | 2006-09-15 | 2008-03-20 | Auriga Laboratories, Inc. | Kits for Prevention and Treatment of Rhinitis |
US20080085312A1 (en) * | 2006-10-04 | 2008-04-10 | Auriga Laboratories, Inc. | Multi-Phase Release Potassium Guaiacolsulfonate Compositions |
KR100836960B1 (en) * | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | A novel controlled release-niacin formulation |
US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
MX2010010214A (en) * | 2008-03-20 | 2010-12-21 | Virun Inc | Vitamin e derivatives and their uses. |
PL2268160T3 (en) * | 2008-03-20 | 2013-05-31 | Virun Inc | Emulsions including a peg-derivative of tocopherol |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
CN103037708B (en) * | 2010-03-23 | 2015-05-20 | 维尔恩公司 | Nanoemulsion including sucrose fatty acid ester |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5047248A (en) * | 1986-03-07 | 1991-09-10 | Eurand Italia S.P.A. | Formulation for preparing sustained release drugs for oral administration |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4795327A (en) | 1984-03-26 | 1989-01-03 | Forest Laboratories, Inc. | Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants |
JPS6124516A (en) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | Long active tablet |
WO1987001936A1 (en) | 1985-09-25 | 1987-04-09 | Gerhard Gergely | Desintegration tablet and process for its manufacture |
US4734285A (en) | 1985-10-28 | 1988-03-29 | The Dow Chemical Company | Sustained release compositions |
US4704285A (en) | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
GB8601204D0 (en) | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
GB2186485B (en) | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
US4855143A (en) | 1986-04-04 | 1989-08-08 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
US4775535A (en) | 1986-04-04 | 1988-10-04 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
US4752479A (en) | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
GB8713169D0 (en) | 1987-06-05 | 1987-07-08 | Peters T J | Uptake of iron by body |
GB8702411D0 (en) | 1987-02-03 | 1987-03-11 | Zyma Sa | Swellable pellets |
US4786518A (en) | 1987-07-02 | 1988-11-22 | The Procter & Gamble Company | Iron mineral supplements |
US4994276A (en) | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
IE60311B1 (en) | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
SE8703881D0 (en) * | 1987-10-08 | 1987-10-08 | Haessle Ab | NEW PHARMACEUTICAL PREPARATION |
DE3809625A1 (en) | 1988-03-22 | 1989-10-05 | Verla Pharm | ORAL-AVAILABLE PHARMACEUTICAL AGENT, IN PARTICULAR FOR IRON AND MAGNESIUM SUBSTITUTION THERAPY |
US5006346A (en) | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5128143A (en) | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5002774A (en) | 1989-06-08 | 1991-03-26 | Erbamont, Inc. | Sustained release pharmaceutical tablet |
US4973470A (en) | 1989-06-26 | 1990-11-27 | Warner-Lambert Company | Sustained release pharmaceutical compositions |
US5077051A (en) | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
JPH0482826A (en) * | 1990-07-26 | 1992-03-16 | Shin Etsu Chem Co Ltd | Sustained releasing tablet |
EP0542926B1 (en) | 1990-08-07 | 1995-02-15 | Pfizer Inc. | Use of interfacially-polymerized membranes in delivery devices |
US5204116A (en) | 1991-05-01 | 1993-04-20 | Alza Corporation | Dosage form providing immediate therapy followed by prolonged therapy |
US5223268A (en) | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
IT1251153B (en) * | 1991-08-06 | 1995-05-04 | Vectorpharma Int | SOLID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION HAVING PROHIBITED GASTRIC RESIDENCE |
JP2669446B2 (en) | 1992-03-23 | 1997-10-27 | 信越化学工業株式会社 | Raw material powder for pharmaceutical coating liquid |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5292534A (en) | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
SE9301220D0 (en) | 1993-04-14 | 1993-04-14 | Kabi Pharmacia Ab | MANUFACTURING MATRICES |
IT1264696B1 (en) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
HU213407B (en) | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
DE19509807A1 (en) | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US5700832A (en) | 1994-10-19 | 1997-12-23 | Daewon Pharm. Co., Ltd. | Antianemic agent containing iron and difructose |
IL139728A (en) | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
IT1282650B1 (en) | 1996-02-19 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS |
CA2173818A1 (en) | 1996-04-10 | 1997-10-11 | Francois Chouinard | Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose |
US5895663A (en) | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
US5851555A (en) | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
-
1999
- 1999-12-10 JP JP2000586311A patent/JP2002531491A/en active Pending
- 1999-12-10 WO PCT/US1999/029372 patent/WO2000033818A1/en active IP Right Grant
- 1999-12-10 DE DE69940557T patent/DE69940557D1/en not_active Expired - Lifetime
- 1999-12-10 EP EP99968872A patent/EP1137403B1/en not_active Expired - Lifetime
- 1999-12-10 CA CA002354057A patent/CA2354057C/en not_active Expired - Fee Related
- 1999-12-10 NZ NZ512288A patent/NZ512288A/en not_active IP Right Cessation
- 1999-12-10 AU AU27079/00A patent/AU772891B2/en not_active Ceased
- 1999-12-10 US US09/459,300 patent/US6416786B1/en not_active Expired - Lifetime
- 1999-12-10 AT AT99968872T patent/ATE424810T1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5047248A (en) * | 1986-03-07 | 1991-09-10 | Eurand Italia S.P.A. | Formulation for preparing sustained release drugs for oral administration |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7985421B2 (en) | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US8012504B2 (en) | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7985420B2 (en) | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7838032B2 (en) | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
EP1385486A1 (en) * | 2001-04-18 | 2004-02-04 | Nostrum Pharmaceuticals, Inc. | A novel coating for a sustained release pharmaceutical composition |
EP1385486A4 (en) * | 2001-04-18 | 2006-05-17 | Nostrum Pharmaceuticals Inc | A novel coating for a sustained release pharmaceutical composition |
US7491383B2 (en) | 2001-05-03 | 2009-02-17 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
EP1503739A1 (en) * | 2002-04-15 | 2005-02-09 | Adams Laboratories, Inc. | Sustained release of guaifenesin combination drugs |
JP2005528402A (en) * | 2002-04-15 | 2005-09-22 | アダムス ラボラトリーズ,インコーポレーテッド | Sustained release of guaifenesin combination |
WO2003088952A1 (en) | 2002-04-15 | 2003-10-30 | Adams Laboratories, Inc. | Sustained release of guaifenesin combination drugs |
EP1503739A4 (en) * | 2002-04-15 | 2006-06-21 | Adams Respiratory Therapeutics | Sustained release of guaifenesin combination drugs |
EP1646367A2 (en) * | 2003-07-21 | 2006-04-19 | Bio-Dar Ltd. | Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
EP1646367A4 (en) * | 2003-07-21 | 2011-06-15 | Nesher Solutions Ltd | Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
WO2007120385A3 (en) * | 2006-02-17 | 2008-01-03 | Kos Life Sciences Inc | Low flush niacin formulation |
WO2007120385A2 (en) * | 2006-02-17 | 2007-10-25 | Kos Life Sciences, Inc. | Low flush niacin formulation |
RU2467750C2 (en) * | 2006-02-17 | 2012-11-27 | Аббот Респирэтори эЛэЛСи | Niacin-containing pharmaceutical composition (versions) and tablet preparation, method for reducing hyperemia and method for preparing niacin-containing tablet |
US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
Also Published As
Publication number | Publication date |
---|---|
EP1137403A1 (en) | 2001-10-04 |
WO2000033818A9 (en) | 2001-02-01 |
CA2354057C (en) | 2009-02-10 |
ATE424810T1 (en) | 2009-03-15 |
EP1137403B1 (en) | 2009-03-11 |
US6416786B1 (en) | 2002-07-09 |
CA2354057A1 (en) | 2000-06-15 |
NZ512288A (en) | 2003-09-26 |
DE69940557D1 (en) | 2009-04-23 |
EP1137403A4 (en) | 2005-10-26 |
JP2002531491A (en) | 2002-09-24 |
AU772891B2 (en) | 2004-05-13 |
AU2707900A (en) | 2000-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6416786B1 (en) | Sustained release tablet containing hydrocolloid and cellulose ether | |
EP0360562B1 (en) | Directly compressible sustained release excipient | |
US5128143A (en) | Sustained release excipient and tablet formulation | |
US5135757A (en) | Compressible sustained release solid dosage forms | |
US5637313A (en) | Chewable dosage forms | |
AU675370B2 (en) | Sustained release formulations for 24 hour release of metoprolol | |
US5169639A (en) | Controlled release verapamil tablets | |
CA2018167C (en) | Sustained release pharmaceutical tablet | |
US20110071137A1 (en) | Process for preparing sustained release tablets | |
US7179486B1 (en) | Process for preparing sustained release tablets | |
HU226375B1 (en) | Once-day metoprolol tablet | |
US20030077324A1 (en) | Control release formulation containing a hydrophobic material as the sustained release agent | |
JPH0513132B2 (en) | ||
MXPA06012448A (en) | Process for the selective increase of a release rate of an active material from a pharmaceutical composition. | |
US20050202079A1 (en) | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation | |
NZ542176A (en) | Control release formulation containing a hydrophobic material as the sustained release agent | |
HRP920377A2 (en) | Process for the preparatin of a carrier base material for drug dosage forms with an extended release of active substance | |
MXPA94008792A (en) | Sustained release formulations for 24 hours of metopro release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2354057 Country of ref document: CA Ref country code: CA Ref document number: 2354057 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999968872 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 27079/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 586311 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 512288 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1999968872 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 27079/00 Country of ref document: AU |